

015
MAY 2 1992
PATENT & TRADEMARK

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

MARK B. WILSON
PARTNER

INTERNET ADDRESS:
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035


1644
HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

COPY OF PAPERS
ORIGINALLY FILED

5/21/02

May 8, 2002

FILE: EPCL:001USC2

| CERTIFICATE OF MAILING 37 C.F.R. 1.8 | |
|---|---|
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below: | |
| May 8, 2002 |  |
| Date | Mark B. Wilson |

RECEIVED
MAY 23 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

RE: *U.S. Patent Application No. 09/989,902 entitled "THERAPEUTIC SYSTEMS USING ENZYMATICALLY-ACTIVE COMPOUNDS CAPABLE OF RELEASING CYANIDE FROM A CYANOGENIC PRODRUG HAVING A PORTION ABLE TO TARGET A CELL" - Agamemnon A. Epenetos and Gail Rowlinson-Busza. (Client Reference: ANTT/P13199U1)*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111745/MBW.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/cmb

Encl: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Agamemnon A. Epenetos
Gail Rowlinson-Busza

Serial No.: 09/989,902

Filed: November 19, 2001

For: THERAPEUTIC SYSTEMS USING
ENZYMATICALLY-ACTIVE
COMPOUNDS CAPABLE OF
RELEASING CYANIDE FROM A
CYANOGENIC PRODRUG HAVING A
PORTION ABLE TO TARGET A CELL


Group Art Unit: 1644

Examiner: Unknown

Atty. Dkt. No.: EPCL:001USC2/MBW

RECEIVED
MAY 23 2002
TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

| | |
|--|--|
| CERTIFICATE OF MAILING 37 C.F.R. 1.8 | |
| I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below: | |
| May 8, 2002 |  |
| Date | Mark B. Wilson |

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10111745/MBW.

This application is a continuation application of Serial No. 08/291,332, filed August 17, 1994, which is a continuation of Serial No. 07/910,303 filed September 23, 1992, and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial Nos. 08/291,332 and 07/910,303.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 8, 2002



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
EPCL:001USC2/MBWSerial No.
09/989,902Applicant
Agamemnon A. Epenetos
Gail Rowlinson-BuszaFiling Date:
November 19, 2001Group:
1644

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Name | Class | Sub Class | Filing Date of App. |
|-------------|-----------|-----------------|------|------|-------|-----------|---------------------|
| | | | | | | | |

Foreign Patent Documents

| Exam. Init. | Ref. Des. | Document Number | Date | Country | Class | Sub Class | Translation Yes/No |
|-------------|-----------|-----------------|---------|---------|-------|-----------|--------------------|
| | B1 | CA 1,216,791 | 1/20/87 | Canada | | | |
| | B1 | EP 0142905 | 5/29/85 | Europe | | | |
| | B1 | EP 0302473 | 8-3-88 | Europe | | | |
| | B1 | WO 87/03205 | 6-4-87 | PCT | | | |
| | B1 | WO 88/07378 | 10-6-88 | PCT | | | |

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C1 | Ardenne <i>et al.</i> , "Tumour hyperacidulation through intravenous glucose infusion enhanced by amygdalin and beta-glucosidase application," <i>Arch Geschwulstforsch.</i> , (abstract) 45(2): 135-145, 1975. |
| | C2 | Bagshawe <i>et al.</i> "Antibody directed enzyme prodrug therapy: a pilot-scale clinical trial," <i>Tumor Targeting</i> , 1:17-29, 1995. |
| | C3 | Bagshawe <i>et al.</i> , "A cytotoxic agent can be generated selectively at cancer sites," <i>Br. J. Cancer</i> , 58:700-703, 1988. |
| | C4 | Bagshawe, K. D., "Antibody directed enzymes revive anti-cancer prodrugs concept," <i>Br. J. Cancer</i> , 56:531-531, 1987. |
| | C5 | Bamias <i>et al.</i> , "Intravesial administration of radiolabeled antitumor monoclonal antibody in bladder carcinoma," <i>Cancer Res.</i> 51:724-728, 1991. |
| | C6 | Biotechnology Business News, pp 1 & 11, 1991. |

25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

COPY OF PAPERS
ORIGINALLY FILED



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

EPCL:001USC2/MBW

Serial No.

09/989,902

Applicant

Agamemnon A. Epenetos

Gail Rowlinson-Busza

Filing Date:

November 19, 2001

Group:

1644

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C7 | Butschak <i>et al.</i> , "Cleavage of alpha-L-arabinofuranoside, beta-D-glucopyranoside and beta-cellobioside of 4-nitrophenol by enzymes of various fungi - A contribution to increase the selectivity of tumor therapy," (abstract), <i>Z. Allg. Mikrobiol.</i> , 16:507-519, 1976. |
| | C8 | Campbell, "Monoclonal antibody technology," Elsevier Press, pp.151-165, 1984. |
| | C9 | Carlet <i>et al.</i> , "Protease-activated 'prodrugs' for cancer chemotherapy," <i>Proc. Natl. Acad. Sci. USA</i> , 77:2224-2228, 1980. |
| | C10 | Chahinian <i>et al.</i> , "Usefulness of the nude mouse model in mesothelioma based on a direct patient-Xenograft comparison," <i>Cancer</i> , 68:558-560, 1991. |
| | C11 | Chopin <i>et al.</i> , "Detection of transitional cell carcinoma in bladder by intravesical injection of monoclonal antibodies," <i>Urol. Res.</i> , (abstract) 14(3):145-148, 1986. |
| | C12 | Connors, "Antitumour drugs with latent activity," <i>Biochemie</i> , 60:980-987, 1978. |
| | C13 | Cox and Farmer, "Towards selectivity? Approaches to the design of new anti-tumour agents-I," <i>Cancer Treatment Rev.</i> , 4:47-63, 1977. |
| | C14 | Curti, "Physical barriers to drug delivery in tumors," <i>Critical Reviews in Oncology/Hematology</i> , 14:29-39, 1993. |
| | C15 | Dermer, "Another anniversary for the war on cancer," <i>Bio/Technology</i> , 12:320, 1994. |
| | C16 | Edington, "How sweet it is: selectin-meidating drugs," <i>Bio/Technology</i> , 10:383-389, 1992. |
| | C17 | English translation of Von Ardenne & Reitnauer, pp.1-16. |
| | C18 | Foon, "Biological response modifiers: The new immunotherapy," <i>Cancer Res.</i> , 49:1621-1639, 1989. |
| | C19 | Ghanem <i>et al.</i> , "Human melanoma targeting with α -MSH-melphanlan conjugate," <i>Melanoma Res.</i> , 1:105-114, 1991. |
| | C20 | Ghose and Blair, "Antibody-linked cytotoxic agents in the treatment of cancer: Current status and future prospects," <i>J. Natl. Cancer Inst.</i> , 67:657-676, 1978. |
| | C21 | Gregoriadis, "Targeting of Drugs," <i>Nature</i> , 265:407-411, 1977. |
| | C22 | Harris <i>et al.</i> , "Therapeutic antibodies - the coming of age," <i>TIBTECH</i> , 11:42-44, 1993. |

25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.

EPCL:001USC2/MBW

Serial No.

09/989,902

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Agamemnon A. Epenetos

Gail Rowlinson-Busza

RECEIVED

Filing Date:

November 19, 2001

Group:

1644

MAY 23 2002

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C23 | Hird and Epenetos, "Immunotherapy with monoclonal antibodies," Chapter 17 In: <i>Genes and Cancer</i> , Carney <i>et al.</i> (eds.), John Wiley and Sons, 183-189, 1990. |
| | C24 | Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993. |
| | C25 | Jain, "Barriers to drug delivery in solid tumors," <i>Sci. America</i> , 271:58-65, 1994. |
| | C26 | Kerr <i>et al.</i> , "Antibody penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxycetamide," <i>Cancer Immunol. Immunother.</i> , 31:202-206, 1990. |
| | C27 | Knowles <i>et al.</i> , "In vitro antibody-enzyme conjugates with specific bactericidal activity," <i>J. Clin. Invest.</i> , 52:1443-1452, 1973. |
| | C28 | Kuefner <i>et al.</i> , "Carboxypeptidase-mediated release of methotrexate from methoxytexasate α -peptides," <i>Biochemistry</i> , 28:2288-2297, 1989. |
| | C29 | Lakow and Basch, "Positive immunoselection using antibody-enzyme complexes," <i>J. Immunol. Meth.</i> , 44:135-151, 1981. |
| | C30 | Lal <i>et al.</i> , "Selective elimination of lymphocyte subpopulations by monoclonal antibody-enzyme conjugates," <i>J. Imm. Methods</i> , 79:307-318, 1985. |
| | C31 | Liebert <i>et al.</i> , "The monoclonal antibody BQ16 identifies the $\alpha 6 \beta 4$ integrin on bladder cancer," <i>Hybridoma</i> , 12(1):67-80, 1993. |
| | C32 | Lyle and Parker, "New approaches to immunosuppression," <i>Fed. Proc.</i> , 33:1889-1893, 1974. |
| | C33 | Moertel <i>et al.</i> , "A clinical trial of amygdalin 9laetirle) in the treatment of human cancer," <i>N. Engl. J. Med.</i> , 306:201-206, 1982. |
| | C34 | Osband and Ross, "Problems in the investigational study and clinical use of cancer immunotherapy," <i>Imm. Today</i> , 11:103-105, 1990. |
| | C35 | Parker <i>et al.</i> , "Enzymatic activation and trapping of luminol-substituted peptides and proteins. A possible means of amplifying the cytotoxicity of the anti-tumor antibodies," <i>Proc. Natl. Acad. Sci. USA</i> , 72:338-342, 1975. |
| | C36 | Parker <i>et al.</i> , "The immunologic therapy of cancer," <i>Pharmacology and the Future of Man</i> , 5:411-419, 1973. |


25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
EPCL:001USC2/MBWSerial No.
09/989,902List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Agamemnon A. Epenetos
Gail Rowlinson-BuszaFiling Date:
November 19, 2001Group:
1644

RECEIVED

MAY 23 2002

TECH CENTER 1600/2900

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|---|
| | C37 | Parker <i>et al.</i> , "The immunotherapy of cancer," <i>Pharmacol. Rev.</i> , 25:325-342, 1973. |
| | C38 | Parker, "Immunologically directed cell destruction," <i>Immunologic Intervention</i> , 176-206, 1971. |
| | C39 | Paulus, <i>Int. Mitt.</i> , 78, 118-132, 1985. |
| | C40 | Philpott <i>et al.</i> , "Affinity cytotoxicity of tumour cells with antibody-glucose oxidase conjugates, peroxidase and arspenamine," <i>Cancer Res.</i> , 34: 2159-2164, 1974. |
| | C41 | Philpott <i>et al.</i> , "Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates," <i>J. Immunol.</i> , 125:1201-1209, 1980. |
| | C42 | Philpott and Parker, "Affinity cell killing with an antibody-alcohol dehydrogenase conjugate and allyl alcohol," <i>Proceedings of AACR and ASCO</i> , 81:21, 1975. |
| | C43 | Philpott <i>et al.</i> , "Affinity cytotoxicity with an alcohol dehydrogenase antibody conjugate and allyl alcohol," <i>Cancer Res.</i> , 39:2084-2089, 1979. |
| | C44 | Philpott <i>et al.</i> , "Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate," <i>J. Immunol.</i> , 111:921-929, 1973. |
| | C45 | Poulton, "Cyanogenesis in plants," <i>Plant Physiol.</i> , 94:401-405, 1990. |
| | C46 | Poulton, "Localization and catabolism of cyanogenic glycosides," <i>Ciba Foundation Symposium 140</i> , pp.67-91, 1988. |
| | C47 | Poupon <i>et al.</i> , "Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates," <i>J. Natl Cancer Institute</i> , 85(24):2023-2029, 1993. |
| | C48 | Riethmuller <i>et al.</i> , "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," <i>Lancet</i> , 343:1177-1183, 1994. |
| | C49 | Rowlinson-Busza <i>et al.</i> , "Antibody guided enzymes activation of amygdalin," <i>Eur J. Cancer</i> , 26:1020,1190 |
| | C50 | Rowlinson-Busza <i>et al.</i> , "Cytotoxicity following specific activation of amygdalin," Chapter 18, In: <i>Monoclonal Antibodies: Applications in Clinical Oncology</i> , Epenetos (ed.), Chapman and Hall, 179-183, 1991. |
| | C51 | Senter <i>et al.</i> , "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate," <i>Proc. Natl. Acad. Sci., USA</i> , 85:4842-4846, 1988. |


25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

Atty. Docket No.
EPCL:001USC2/MBWSerial No.
09/989,902List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENTApplicant
Agamemnon A. Epenetos
Gail Rowlinson-Busza

RECEIVED

Filing Date:
November 19, 2001Group: MAY 23 2002
1644

(Use several sheets if necessary)

U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

TECH CENTER 1600/2900

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

| Exam. Init. | Ref. Des. | Citation |
|-------------|-----------|--|
| | C52 | Senter <i>et al.</i> , "Enchantment of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphates conjugates," <i>Cancer Res.</i> , 49:5789-5792, 1989. |
| | C53 | Senter, "Activation of prodrugs by antibody-enzymes conjugates: a new approach to cancer therapy," <i>FASEB J.</i> , 4:188-193, 1990. |
| | C54 | Senter, "The present and future role of monoclonal antibodies in the management of cancer," <i>Front. Radial. Ther. Oncol.</i> , 24:133-141, 1990. |
| | C55 | Shearer <i>et al.</i> , "Cytotoxicity with antibody-glucose oxidase conjugates specific for human colonic cancer and carcinoembryonic antigen," <i>Int. J. Cancer</i> , 14:539-547, 1974. |
| | C56 | Simpson, <i>Genetic Engineering News</i> , 1:7, 1991. |
| | C57 | Spurr <i>et al.</i> , "Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody auai," <i>Int. J. Cancer</i> , 38:631-636, 1986. |
| | C58 | Sullivan <i>et al.</i> , "Specific killing of parasites by antibody-enzyme conjugates," <i>Res. Comm. Chem. Pathol.</i> , 6:709-717, 1973. |
| | C59 | Thorpe <i>et al.</i> , "Comparison of two anti-Thy 1.1-Abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants," <i>JNCI</i> , 79(5):1101-1112, 1987. |
| | C60 | Waldmann <i>et al.</i> , "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> , 252:1657-1662, 1991. |

COPY OF PAPERS
ORIGINALLY FILED

25147165.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)